We believe in the importance of collaborations among people. All the work wouldn't be possible without our past and present members. If you want to join our team, you can take a look here.
Simona Sestito, PhD
Simona Sestito graduated with honours in Pharmaceutical Chemistry and Technology in April 2011 at University of Pisa, and started the Doctoral course in "Science of Drug and Bioactive Substances" at the University of Pisa in the same year. In october 2013 (for 8 months) she was a visiting student at the Blizard Institute of the Queen Mary University of London under supervision Prof. Falasca to study the effects of new Akt/PDK1 inhibitors on pancreatic cancer and breast cancer cell lines. In March 2015 she obtained the title of PhD , defending a dissertation entitled "Design and synthesis of new antitumor ligands" . Since then she is a Postdoctoral Researcher at the Laboratories of Medicinal Chemistry of the Department of Pharmacy, University of Pisa. Actually, she is working on two main projects: the development of new multitarget agents and prodrugs endowed with antitumor activity; and development of new potential drugs for the prevention of cellular aging and neurodegeneration.
Massimiliano Runfola graduated in June 2016 in CTF (Pharmaceutical Chemistry and Technology) at University of Pisa. Since November 2017 he is a doctoral student at Department of Pharmacy of University of Pisa, under supervision of Professor Rapposelli. His main project focuses on the design, synthesis, and biological evaluation of new compounds for treatment of neurodegenerative disorders. The main topic of his research activity is the optimization of thyronamine-like analogues, namely SG compounds, which proved to hit the main impaired pathways involved in AD .
Andrea Bacci graduated in April 2018 in CTF (Pharmaceutical Chemistry and Technology) at University of Pisa. In November 2019 he started his PhD course at the doctoral school of Science of Drug and Bioactive Substances at Department of Pharmacy of University of Pisa, under supervision of Professor Rapposelli. The aim of his project is to design and synthetize dual BTK-TCL1 inhibitors able to directly act against the mutated BTK forms, but also against the AKT and NF-kB pathway activation, indirectly mediated by TCL1.